Spotlight: Bridging proof and progress: Why promising CGTs still stall and how smarter trial infrastructure unlocks flow

Proof isn’t the problem progress is: Why even well-validated CGT programmes (including late-stage assets) still stall between Phase I and II, and how trial infrastructure, not science, is increasingly the limiting factor.

Hidden friction in trial execution: Where CGT trials lose time and momentum today from site readiness and vein-to-vein complexity to data fragmentation and cross-border logistics and why these issues compound at scale.

Designing trials for flow, not heroics: How rethinking trial operations, digital oversight and coordination early can materially improve speed, data quality and regulator confidence without increasing burden on sites or patients.

What ‘ready for scale’ really means: The practical infrastructure capabilities CGT trials now need to move smoothly from early clinical development into pivotal studies and beyond.